Clinical trial
The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy…
NCT00375505 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00375505 |
|---|---|
| Title | The Safety and Efficacy of Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss |
| Official title | Zoledronic Acid in the Prevention of Cancer Therapy Induced Bone Loss |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | Zoledronic acid, Placebo |
| Enrollment | 70 |
| Start date | Oct 1, 2005 |
| Primary completion | May 1, 2014 |
| Completion | May 1, 2014 |
| First posted | Sep 13, 2006 |
| Last update posted | Sep 7, 2015 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: